Rituximab and Pirfenidone in the Treatment of Steroid-Refractory Bleomycin Lung Injury

利妥昔单抗和吡非尼酮治疗类固醇难治性博来霉素肺损伤

阅读:5

Abstract

Bleomycin-induced lung injury (BILI) is a well-recognised but potentially life-threatening complication of ABVD chemotherapy (adriamycin, bleomycin, vinblastine and dacarbazine), often requiring prompt diagnosis and intervention. We present a case of a 43-year-old female with Hodgkin's lymphoma who developed progressive respiratory symptoms following her fourth cycle of ABVD. A broad infectious and autoimmune workup was unremarkable, and chest imaging was consistent with interstitial lung disease. Her condition deteriorated despite empirical antibiotics and high-dose corticosteroids. The addition of rituximab and pirfenidone led to significant clinical and radiological improvement, highlighting the potential role of these agents in managing steroid-refractory BILI.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。